Conduit Pharmaceuticals Inc.
CDT
$0.6201
-$0.16-20.51%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 130.59% | 112.79% | 63.56% | 61.74% | 83.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 186.32% | 179.82% | 66.96% | 65.41% | 84.35% |
| Operating Income | -186.32% | -179.82% | -66.96% | -65.41% | -84.35% |
| Income Before Tax | -1,860.57% | -258.69% | 22.29% | 55.41% | 81.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1,860.57% | -258.69% | 22.29% | 55.41% | 81.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,860.57% | -258.69% | 22.29% | 55.41% | 81.42% |
| EBIT | -186.32% | -179.82% | -66.96% | -65.41% | -84.35% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1,345.96% | -150.92% | 46.96% | 67.22% | 82.92% |
| Normalized Basic EPS | -1,342.62% | -135.92% | 48.35% | 68.32% | 83.65% |
| EPS Diluted | -141.74% | -108.76% | -2.96% | 2.87% | -2.60% |
| Normalized Diluted EPS | -1,364.99% | -136.98% | 47.74% | 68.34% | 83.90% |
| Average Basic Shares Outstanding | 29.44% | 24.46% | 33.53% | 84.99% | 214.57% |
| Average Diluted Shares Outstanding | 27.44% | 24.06% | 33.75% | 87.04% | 219.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |